Gene therapy for the treatment of chronic peripheral nervous system pain.
Gene therapy for the treatment of chronic peripheral nervous system pain.
复制标题
DOI：
10.1016/j.nbd.2012.05.005
复制
发表时间：
2012-11
影响因子：
6.1
通讯作者：
Glorioso, Joseph C.
中科院分区：
文献类型：
--
作者：
Goins, William F.;Cohen, Justus B.;Glorioso, Joseph C.
关键词：
慢性疼痛是一个主要的健康问题，影响8000万美国人在他们的生活中的某个时候与显着相关的发病率和对个人生活质量的影响。慢性疼痛可由多种炎症和神经损伤事件引起，包括癌症、传染病、自身免疫相关综合征和手术。目前的药物治疗尚未提供有效的长期解决方案，因为它们受到药物耐受性和潜在滥用的限制。这些问题导致了基因治疗方法的开发和测试，以治疗慢性疼痛。基因治疗疼痛的潜在疗效已经在许多临床前研究中报道，这些研究表明在脊髓水平控制疼痛。这一承诺最近得到了I期人体试验的支持，其中复制缺陷型单纯疱疹病毒（HSV）载体用于将编码天然阿片肽甲硫氨酸和亮脑啡肽（ENK）的人前脑啡肽原（hPPE）基因递送给患有骨转移引起的顽固性疼痛的癌症患者。该研究表明，该疗法耐受性良好，并且接受较高剂量治疗载体的患者在载体注射后长达一个月的时间内总体疼痛评分大幅降低。这些令人兴奋的早期临床结果有待进一步的患者测试，以证明治疗效果，并可能为其他治疗慢性疼痛的基因疗法铺平道路。
Chronic pain is a major health concern affecting 80 million Americans at some time in their lives with significant associated morbidity and effects on individual quality of life. Chronic pain can result from a variety of inflammatory and nerve damaging events that include cancer, infectious diseases, autoimmune-related syndromes and surgery. Current pharmacotherapies have not provided an effective long-term solution as they are limited by drug tolerance and potential abuse. These concerns have led to the development and testing of gene therapy approaches to treat chronic pain. The potential efficacy of gene therapy for pain has been reported in numerous pre-clinical studies that demonstrate pain control at the level of the spinal cord. This promise has been recently supported by a Phase-I human trial in which a replication-defective herpes simplex virus (HSV) vector was used to deliver the human pre-proenkephalin (hPPE) gene, encoding the natural opioid peptides met- and leu-enkephalin (ENK), to cancer patients with intractable pain resulting from bone metastases. The study showed that the therapy was well tolerated and that patients receiving the higher doses of therapeutic vector experienced a substantial reduction in their overall pain scores for up to a month post vector injection. These exciting early clinical results await further patient testing to demonstrate treatment efficacy and will likely pave the way for other gene therapies to treat chronic pain.
登录
查看更多内容
DOI：
10.1016/j.jpain.2008.10.008
发表时间：
2009-02
期刊：
The journal of pain
影响因子：
--
作者：
Chou R;Fanciullo GJ;Fine PG;Adler JA;Ballantyne JC;Davies P;Donovan MI;Fishbain DA;Foley KM;Fudin J;Gilson AM;Kelter A;Mauskop A;O'Connor PG;Passik SD;Pasternak GW;Portenoy RK;Rich BA;Roberts RG;Todd KH;Miaskowski C;American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel
通讯作者：
American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel
影响因子：
2.1
作者：
Chuang, YC;Yang, LC;Yoshimura, N
通讯作者：
Yoshimura, N
DOI：
10.1016/j.ejpain.2011.03.007
发表时间：
2011-10
期刊：
European journal of pain (London, England)
影响因子：
--
作者：
Chattopadhyay M;Mata M;Fink DJ
通讯作者：
Fink DJ
影响因子：
3.3
作者：
Chattopadhyay M;Zhou Z;Hao S;Mata M;Fink DJ
通讯作者：
Fink DJ
影响因子：
5.1
作者：
Alba, R;Bosch, A;Chillon, M
通讯作者：
Chillon, M